COMPARE · Data as of August 12, 2026
GENB vs HRMY
Verdict: Side-by-side breakdown using the Bull Rankings model. GENB scored 25.7, HRMY scored 90.4 — HRMY leads.
Compare another set
GENB
Generate Biomedicines, Inc.
25.7
$15.09 · $1.9B
fundamentals as of
Score gap
64.7
HRMY leads
HRMY
Harmony Biosciences Holdings, Inc.
90.4
$39.77 · $2.3B
fundamentals as of
The model, pillar by pillar (0–100 each)
GENB
stronger →← stronger
HRMY
34
Qualityreturns · margins · balance sheet
80
100
Growthrevenue & earnings expansion
100
2
Valuevaluation vs sector peers
93
HRMY is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
GENB
HRMY
-$246mF
FCF
$355mC
+55.9%A
Rev
+24.3%A-
0.14B+
D/E
0.16B+
73.1xD
P/S
—
—
PEG
0.59A-
—
P/E
12.9xA-
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
GENB
HRMY
—
Price vs fair valuelower is cheaper
74% below
—
Growth the price implies10-yr FCF · lower = less priced in
~-17%/yr
—
1-yr DCF upside
+194%
—
5-yr DCF upside
+287%
—
10-yr DCF upside
+481%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
GENB
Why this score
- Short track record
HRMY
Why this score
- Durable high returns
The companies
GENBGenerate Biomedicines, Inc.
Why now
Biotechnology · market cap $1.9b. 17% off the 52-week high of $18.18. Revenue growing +56% — in hypergrowth territory. 5 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $25.60 (implying +70% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$246m) — capital raises or debt issuance likely required; dilution / leverage risk. P/S 73.1x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HRMYHarmony Biosciences Holdings, Inc.
Why now
Biotechnology · market cap $2.3b. Trading near 52-week high of $40.87 — momentum setup, limited technical margin of safety. Revenue growing +24%, comfortably above the S&P median. PEG 0.59 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $46.10 (implying +16% upside).
Moat
Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 196% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 3% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where GENB and HRMY diverge
On the headline score the gap is 64.7 points in favour of HRMY. The widest single difference is Value, where HRMY leads by 90.4 points.
- ValueGENB 2.3 · HRMY 92.7HRMY +90.4
- QualityGENB 33.9 · HRMY 79.7HRMY +45.8
- GrowthGENB 100.0 · HRMY 100.0level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.